Qingyuan Zhang

8PUBLICATIONS
44CO-AUTHORS
Gene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Sep 09, 2026
Neoadjuvant Pertuzumab Biosimilar HLX11 Versus Reference Pertuzumab for Early-stage or Locally Advanced Breast Cancer: A phase 3 Equivalence Trial.

|Jan 28, 2026
Becotatug Vedotin in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Multicenter, Phase IIa Trial.

Liqiong Xue, Yaqian Han, Qingyuan Zhang

|Dec 06, 2024
Efficacy and Safety of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Previously Untreated Diffuse Large B-Cell Lymphoma: A Real-World, Multi-Center, Retrospective Cohort Study.

Peiqi Zhao, Shu Zhao, Chen Huang

|Feb 01, 2022
Serum amyloid A 1 induces suppressive neutrophils through the Toll-like receptor 2-mediated signaling pathway to promote progression of breast cancer.

Xingjian Niu, Lei Yin, Xudong Yang

|May 19, 2021
Sodium/glucose cotransporter 1-dependent metabolic alterations induce tamoxifen resistance in breast cancer by promoting macrophage M2 polarization.

Xingjian Niu, Jianli Ma, Jingtong Li

|Jan 16, 2021
HMGB1 is a key factor for tamoxifen resistance and has the potential to predict the efficacy of CDK4/6 inhibitors in breast cancer.

Han Zhang, Jinlu Wang, Jingtong Li

Pageof 2

Frequent Collaborators

1 joint publications

Dongbo Li

1 joint publications

Han Zhang

1 joint publications

Hongfei Ji

1 joint publications

Peiqi Zhao